Clinical trial
A Multi-center, Randomized and Controlled Phase IV Study on the Efficacy and Safety of Two Dose Adjustment Regimens of Nicardipine Injection for Hypertensive Emergency
NCT01872039 is registered in ClinicalTrials.gov with Astellas Pharma China, Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Multi-center, Randomized and Controlled Phase IV Study on the Efficacy and Safety of Two Dose Adjustment Regimens of Nicardipine Injection for Hypertensive Emergency
- Lead sponsor
- Astellas Pharma China, Inc.
- Phase
- Phase 4
- Overall status
- Completed
- Start date
- March 31, 2013
- Completion date
- January 31, 2014
- Enrollment
- 163 (actual)
- Sites
- 5
Conditions
As the registry lists them; a condition with its own page is linked.
end-organ damage, hypertension emergency